The prefilled syringes market is projected to reach US$20,323.33 million by 2034 from US$8,836.00 million in 2025. The market is estimated to register a CAGR of 9.9% during 2026-2034.

Major factors driving the market growth include the rising prevalence of chronic diseases, as well as advancements in biologics and biosimilars, and increasing adoption of self-administration and home healthcare are propelling the adoption of prefilled syringes. Further, expanded vaccination programs and public health initiatives will likely boost the market during the forecast period. However, high manufacturing and development costs and stringent regulatory requirements, and approval delays are among the market deterrents.

Advancements in biologics and biosimilars are leading to the development of stable, user-friendly delivery systems for complex proteins and monoclonal antibodies, with prefilled syringes minimizing degradation, ensuring sterility, and facilitating precise administration in therapeutic areas such as oncology and autoimmune diseases. According to the WHO, in 2022, noncommunicable diseases such as cancer (linked to biologics) caused 74% of global deaths, with biologics used for targeted therapies. According to the U.S. FDA, in 2023, 37 new biologics were approved, many requiring injectable formats. According to the EMA, in 2024, biosimilar approvals rose, with 15 new biosimilars authorized, often in prefilled syringes for cost-effective access. According to the CDC, in the US in 2022, cancer prevalence affected 18.1 million survivors, driving biologic demand. In India, according to the Indian Council of Medical Research, cancer incidence reached 1.46 million cases in 2022, increasing reliance on injectable biologics. New product developments exemplify this: according to the U.S. FDA, in February 2024, denosumab biosimilars (Samsung Bioepis) were approved in prefilled syringes for bone metastases. According to the EMA, in 2023, ustekinumab biosimilars (Pyzchiva) gained approval in prefilled syringes for autoimmune conditions. Other instances include the FDA's 2024 approval of efgartigimod prefilled syringe for myasthenia gravis, a biologic for rare diseases, and EMA's 2022 endorsement of guidelines promoting biosimilar prefilled formats to enhance affordability.

The comparative company analysis evaluates and categorizes the prefilled syringes market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global Prefilled Syringes market. The key market players are Gerresheimer AG, Schott Group, Nipro Medical Corporation, BD, Baxter International Inc., Terumo, YPSOMED, Weigao Group, Barun, and Deltamed.

Based on type, the prefilled syringes market is bifurcated into disposable prefilled syringes and reusable prefilled syringes. The disposable prefilled syringes segment held a larger prefilled syringes market share in 2025. Disposable prefilled syringes are preferred due to convenience, reduced contamination risk, regulatory preference, lower costs, improved safety, and rising vaccination programs.

By material, the prefilled syringes market includes glass prefilled syringes and plastic prefilled syringes. The glass prefilled syringes segment held a larger prefilled syringes market share in 2025. Glass prefilled syringes ensure drug stability, superior barrier properties, chemical compatibility, regulatory acceptance, and widespread biologics usage.

In terms of product type, the prefilled syringes market is divided into single-chamber and multi-chamber. The single-chamber segment held a larger prefilled syringes market share in 2025. Single-chamber prefilled syringes grow because of simpler design, ease of use, lower manufacturing complexity, reduced costs, and high-volume therapies globally.

By application, the prefilled syringes market is divided into cancer, diabetes, cardiovascular disease, autoimmune disease, infectious disease, and others. Other applications made up a large part of the market in 2025. Other applications are expanding by use in neurological disorders, allergies, dermatological conditions, endocrine disorders, and respiratory diseases, increasing injectable therapy adoption.

By distribution channel, the prefilled syringes market is segmented into hospital pharmacy, retail pharmacy, and online channel. The hospital pharmacy segment made up a large part of the market in 2025. Hospital pharmacy channels grow due to high patient inflow, critical care usage, physician preference, controlled storage, and institutional purchasing power.

Companies operating in the Prefilled Syringes market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses, enhance their geographic presence, and contribute to the overall market growth. Furthermore, acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few significant developments by key Prefilled Syringes market players are listed below.

In October 2025, Becton, Dickinson and Company announced a strategic partnership with Ypsomed, a leading provider of injection systems, to enhance self-injection solutions for high-viscosity biologic drugs. Through a joint initiative, BD and Ypsomed have pre-assessed and optimized the integration of the BD Neopak XtraFlow Glass Prefillable Syringe with Ypsomed's YpsoMate 2.25 autoinjector platform. This collaboration addresses existing challenges by enabling the delivery of biologic drugs with viscosities exceeding 15 cP in autoinjector format.

In March 2024, B. Braun SE collaborated with Orlando Health to co-create innovative solutions that enhance access to care for patients and clinicians. This collaboration will prioritize addressing disruptions in the pharmacy and infusion therapy sectors, emphasizing the collection of early clinician feedback to identify needs and develop tailored solutions.